Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Abeona Therapeutics (ABEO) EBITDA: 2011-2024

Historic EBITDA for Abeona Therapeutics (ABEO) over the last 13 years, with Dec 2024 value amounting to -$63.7 million.

  • Abeona Therapeutics' EBITDA rose 83.10% to -$5.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $82.4 million, marking a year-over-year increase of 216.09%. This contributed to the annual value of -$63.7 million for FY2024, which is 17.62% down from last year.
  • According to the latest figures from FY2024, Abeona Therapeutics' EBITDA is -$63.7 million, which was down 17.62% from -$54.1 million recorded in FY2023.
  • Abeona Therapeutics' 5-year EBITDA high stood at -$43.6 million for FY2022, and its period low was -$85.0 million during FY2021.
  • Its 3-year average for EBITDA is -$53.8 million, with a median of -$54.1 million in 2023.
  • Per our database at Business Quant, Abeona Therapeutics' EBITDA surged by 48.70% in 2022 and then declined by 24.20% in 2023.
  • Yearly analysis of 5 years shows Abeona Therapeutics' EBITDA stood at -$84.2 million in 2020, then dropped by 0.84% to -$85.0 million in 2021, then spiked by 48.70% to -$43.6 million in 2022, then fell by 24.20% to -$54.1 million in 2023, then decreased by 17.62% to -$63.7 million in 2024.